Kymera Therapeutics, Inc.
KYMRNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M | $34.0M |
| Operating income | −$349.4M | −$261.6M | −$165.5M | −$161.3M | −$100.5M | −$46.3M |
| Net income | −$311.4M | −$223.9M | −$147.0M | −$154.8M | −$100.2M | −$45.6M |
| Total assets | $1.74B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M | $203.3M |
| Equity | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M |
| EPS (diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 |
| Shares out. | 64.9M | 61.1M | 55.2M | 51.7M | 44.8M | 44.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −891.1%
- Net margin
- −794.0%
- Return on equity
- −19.7%
- Return on assets
- −17.9%
- Return on capital (ROCE)
- −21.1%
- Liabilities / assets
- 9.4%
- Debt / equity
- 0.10×
- Book value / share
- $24.32
- Revenue growth (YoY)
- −16.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 9.79safe
- Accruals / assets
- −4.5%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-12First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
- Phase 2Recruitingreadout ~2027-06A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
- Phase 2Recruitingreadout ~2027-12A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Wellington Management Group LlpPassive (13G)May 15, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Biotechnology Value Fund L PActivist (13D)Dec 15, 2025
- Baker Bros. Advisors LpActivist (13D)Dec 11, 2025
- Price T Rowe Associates Inc /Md/Passive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chadwick Jeremy GOfficer — Chief Operating Officer | May 26, 2026 | Sell | 3,730 | $78.36 |
| Esposito PamelaDirector | May 19, 2026 | Option exercise | 1,000 | $31.20 |
| Jacobs Bruce N.Officer — Chief Financial Officer | May 18, 2026 | Option exercise | 15,000 | $2.08 |
| Ridloff ElenaDirector | May 11, 2026 | Option exercise | 3,000 | $31.20 |
| Mainolfi NelloOfficer — Chief Executive Officer | Apr 29, 2026 | Option exercise | 30,000 | $2.08 |
| Booth BruceDirector | Apr 22, 2026 | Option exercise | 5,641 | $14.18 |
| Chadwick Jeremy GOfficer — Chief Operating Officer | Apr 22, 2026 | Option exercise | 100 | $30.17 |
| Goodman NoahOfficer — Chief Business Officer | Apr 14, 2026 | Sell | 1,347 | $90.00 |
| Chadwick Jeremy GOfficer — Chief Operating Officer | Apr 14, 2026 | Option exercise | 4,466 | $30.17 |
| Booth BruceDirector | Apr 14, 2026 | Option exercise | 4,159 | $14.18 |
| Goodman NoahOfficer — Chief Business Officer | Apr 9, 2026 | Option exercise | 2,500 | $21.05 |
| Ridloff ElenaDirector | Mar 31, 2026 | Option exercise | 7,400 | $14.18 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10.0M | 21.3 | +3.3% |
| Apr 30, 2026 | 9.7M | 18.8 | +0.7% |
| Apr 15, 2026 | 9.6M | 19.5 | -7.5% |
| Mar 31, 2026 | 10.4M | 14.6 | +4.3% |
| Mar 13, 2026 | 10.0M | 13.8 | -3.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 30, 2026
- Amended charter or bylawsMar 27, 2026
- Entered a material agreement · Terminated a material agreement · Other material eventFeb 26, 2026
- Results of operationsFeb 26, 2026
- Results of operations · Regulation FD disclosureJan 13, 2026
- Entered a material agreement · Other material eventDec 10, 2025
- Regulation FD disclosureDec 8, 2025
- Regulation FD disclosure · Other material eventDec 8, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 27, 2026
- 144May 26, 2026
- 144May 26, 2026
- 4May 19, 2026
- 4May 19, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 4May 11, 2026
- 144May 11, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-QApr 30, 2026
- 8-KApr 30, 2026
- 4Apr 29, 2026
- ARSApr 29, 2026
- DEFA14AApr 29, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.